Breaking News Instant updates and real-time market news.

MSFT

Microsoft

$108.97

3.06 (2.89%)

, NFLX

Netflix

$340.37

19.09 (5.94%)

10:27
10/12/18
10/12
10:27
10/12/18
10:27

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Outperform from Neutral at Macquarie with analyst Sarah Hindlian saying she is taking advantage of the pullback in shares. 2. Netflix (NFLX) upgraded to Buy from Neutral at Citi with analyst Mark May saying the valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy. 3. Square (SQ) upgraded to Buy from Hold at Canaccord with analyst Michael Graham saying the recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company." 4. Snap (SNAP) upgraded to Buy from Hold at Pivotal Research with analyst Brian Wieser saying despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." 5. Costco (COST) upgraded to Buy from Neutral at Northcoast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MSFT

Microsoft

$108.97

3.06 (2.89%)

NFLX

Netflix

$340.37

19.09 (5.94%)

SQ

Square

$74.50

5.38 (7.78%)

SNAP

Snap

$7.32

0.5 (7.33%)

COST

Costco

$225.01

3.15 (1.42%)

  • 16

    Oct

  • 16

    Oct

  • 21

    Oct

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 07

    Nov

  • 07

    Nov

  • 13

    Nov

  • 26

    Nov

  • 28

    Nov

  • 03

    Mar

MSFT Microsoft
$108.97

3.06 (2.89%)

10/12/18
MACQ
10/12/18
UPGRADE
Target $121
MACQ
Outperform
Macquarie upgrades Microsoft to Outperform after pullback to 'correct' mistake
As previously reported, Macquarie analyst Sarah Hindlian upgraded Microsoft to Outperform from Neutral, taking advantage of the market pullback to "correct" her rating on "a name [she has sorely missed." The company has been differentiating Azure in several critical ways that she did not fully appreciate, such as being both enterprise-friendly and aggressive in layering in unique and incremental services such as Artificial Intelligence, Azure Stack, Azure Sphere, and a broad focus on edge computing, Hindlian tells investors. Additionally, Microsoft continues to drive the business into higher-growth arenas, like public cloud and what she expects to be an emerging successful gaming services platform. While many are worrying that the company's robust earnings trend will not persist as comps get tougher, Hindlian sees ample revenue drivers and raised her price target on Microsoft shares to $121 from $106.
10/08/18
FBCO
10/08/18
NO CHANGE
FBCO
Outperform
Global brand ranking validates Microsoft rebranding efforts, says Credit Suisse
Credit Suisse analyst Brad Zelnick notes that, among top global brands, Microsoft (MSFT) ranked fourth in global brand ranking with a brand value of $92.7B, superseded only by Amazon (AMZN), Google (GOOG; GOOGL) and Apple (AAPL). The analyst believes this validates Microsoft's rebranding efforts in the Satya era, distinguished by a more open and flexible approach to customers, rivals as well as application developers. Zelnick reiterates an Outperform rating on Microsoft shares.
10/08/18
BARD
10/08/18
NO CHANGE
BARD
Outperform
Microsoft Project xCloud mostly positive for game publishers, says Baird
After Microsoft (MSFT) announced details of its game-streaming initiative, Project xCloud, Baird analyst Colin Sebastian said he does not expect beta user trials until 2019, with a full launch likely 1-2 years later. The analyst, who sees the news as mostly positive for game publishers Activision Blizzard (ATVI), Electronic Arts (EA) and Take-Two (TTWO), believes that streaming represents an opportunity to convert a portion of the remaining casual gamer market by providing console-quality full streaming games with the cross-platform social features of current consoles. Baird has Outperform ratings on all three game publishers mentioned.
10/12/18
MACQ
10/12/18
UPGRADE
Target $121
MACQ
Outperform
Microsoft upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Sarah Hindlian upgraded Microsoft to Outperform from Neutral and raised its price target to $121 saying she is taking advantage of the pullback in shares. Hindlian views Microsoft as a relatively defensive name with long-term earnings power and expects a strong start to FY19 following constructive field work.
NFLX Netflix
$340.37

19.09 (5.94%)

10/12/18
MKMP
10/12/18
NO CHANGE
Target $395
MKMP
Buy
Netflix set-up attractive ahead of earnings, says MKM Partners
MKM Partners analyst Rob Sanderson kept his Buy rating and $395 price target on Netflix ahead of its earnings next week, saying that after a "meaningful" pullback in its price from the broader market volatility, the stock looks "attractive again". The analyst cites the company's "solid looking performance from the content slate", along with its new content coming and conservative looking expectations relative to its historic seasonality. Sanderson anticipates that Netflix will have many years of market cap appreciation ahead and views its fundamentals "among the best of the mega-caps".
10/12/18
WEDB
10/12/18
NO CHANGE
Target $125
WEDB
Underperform
Netflix's valuation 'unwarranted,' says Wedbush
Wedbush analyst Michael Pachter reiterated an Underperform rating and $125 price target on Netflix ahead of the company's quarterly results, telling investors in a research note that he believes Netflix's valuation is unwarranted and that consistently negative free cash flow makes discounted cash flow valuation "impossible." Pachter says he expects content spending to trigger "substantial" cash burn for many years, and believes international profits may remain "elusive" due to competition for content and subscribers, with future price increases potentially causing a deceleration in subscriber growth.
10/11/18
PIPR
10/11/18
NO CHANGE
Target $420
PIPR
Overweight
Piper search analysis shows Q3 upside for Netflix international subs
Piper Jaffray analyst Michael Olson says his analysis of Netflix search trends points to a "strong" Q3 for internal subscribers, with domestic subs likely in-line. Specifically, consensus calls for 9.9% year-over-year domestic sub growth in Q3 and Piper's search index points to 11.0%. For international, Q3 consensus calls for 36.4% year-over-year sub growth and Piper's index points to 48.5%. The index is directionally positive for international, showing a "high likelihood of a strong" Q3 for Netflix international sub adds, Olson tells investors in a research note. He reiterates an Overweight rating on Netflix with a $420 price target.
10/12/18
SBSH
10/12/18
UPGRADE
Target $375
SBSH
Buy
Netflix upgraded to Buy from Neutral at Citi
Citi analyst Mark May upgraded Netflix to Buy from Neutral with an unchanged price target of $375. The streaming service closed yesterday down $4.79 to $321.10. The valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy, May tells investors in a research note. Netflix has a highly recurring subscription-based revenue business that delivers "significant value" to consumers, and its management team has a strong track record of execution, the analyst contends. Further, he believes the company's fundamentals remain strong and that is has opportunity to continue growing international subscribers.
SQ Square
$74.50

5.38 (7.78%)

10/11/18
WBLR
10/11/18
NO CHANGE
WBLR
Outperform
Sarah Friar 'major loss,' Square shares still expensive, says William Blair
William Blair analyst Robert Napoli views the departure of Sarah Friar as a "major loss" for Square. Friar was critical to the success of the company, its strategic direction, and the management of growth/investment versus margin expansion, Napoli tells investors in a research note. And while stock has pulled back 24% from its recent highs, it remains expensive at 25 times 2018 and 19 times 2019 enterprise value to revenue, Napoli contends. He keeps a Market Perform rating on Square, which is trading down 6%, or $4.85, to $72.60 in the premarket.
10/12/18
ADAM
10/12/18
UPGRADE
Target $90
ADAM
Buy
Square upgraded to Buy from Hold at Canaccord
Canaccord Genuity analyst Michael Graham upgraded Square to Buy from Hold and raised his price target for the shares to $90 from $60. The stock closed yesterday down 11%, or $8.42, to $69.03. The recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company," Graham tells investors in a research note. He believes the departure of CFO Sarah Friar is more about going to a promising company as CEO rather than walking away from a risk. Further, Graham sees "plenty of opportunity" for Graham to grow its core business.
10/12/18
NOMU
10/12/18
NO CHANGE
Target $125
NOMU
Buy
Square selloff yesterday not warranted by CFO exit, says Nomura Instinet
Departing CFO Sarah Friar is important, but certainly not important enough to merit yesterday's selloff in shares of Square, Nomura Instinet analyst Dan Dolev tells investors in a research note titled "Focus on Results Not the CFO." He believes Friar's departure is "unlikely to disrupt the innovation engine behind" the company. The analyst keeps a Buy rating on Square with a $125 price target.
10/11/18
MSCO
10/11/18
NO CHANGE
Target $75
MSCO
Equal Weight
Square likely to be weighed on in near-term by CFO exit, says Morgan Stanley
Morgan Stanley analyst James Faucette gives credit to outbound Square CFO Sarah Friar for managing Wall Street expectations and helping the company deliver consistent "beat and raise" earnings reports. He expects that the stock is likely to be weighed down near-term by the uncertainty around whether the new CFO will be able to match this track record, especially in light of the stock's elevated valuation. Faucette keeps an Equal Weight rating and $75 price target on Square, which is down by about 10% in pre-market trading.
SNAP Snap
$7.32

0.5 (7.33%)

10/11/18
10/11/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN UPGRADES LUMENTUM AFTER SELLOFF: JPMorgan analyst Samik Chatterjee upgraded Lumentum (LITE) to Overweight from Neutral with an unchanged price target of $80. The 19% stock decline from the highs in late August, driven by concerns relative to U.S.-China trade, over-appreciates the "modest risks" for Lumentum, Chatterjee said. He believes this creates an "attractive buying opportunity" to capitalize on the near-term improvement in the earnings outlook. GOLDMAN CUTS HUNTINGTON TO SELL: Goldman Sachs analyst Noah Poponak downgraded Huntington Ingalls Industries (HII) to Sell from Neutral and lowered his price target for the shares to $208 from $220. Poponak said Huntington is now the most expensive stock in his Defense coverage on economic, price-to-earnings and free cash flow yield. The analyst believes the stock could underperform Defense peers in the medium-term given the valuation. JEFFRIES STARTS HERBALIFE WITH A BUY: Jefferies analyst Akshay Jagdale started Herbalife Nutrition (HLF) with a Buy rating and $65 price target. After a period of "muted growth," Herbalife's sales looked poised to accelerate to a more normalized range of 5%-9%, Jagdale believes. He thinks the company should be able to grow at least in line with its total addressable market growth rate of 6%. This, coupled with margin expansion and accretive free cash flow usage, should drive "significant" earnings upside and support a "growth company valuation," Jagdale said. JPMORGAN RAISES PRICE TARGET ON NY TIMES: JPMorgan analyst Alexia Quadrani raised her price target for New York Times (NYT) to $32 and reiterated an Overweight rating on the shares ahead of the company's Q3 results. The analyst said that while quarterly subscriber growth may continue to be volatile, the company's longer-term trends are positive. She expects New York Times' growth to "remain at elevated levels for the foreseeable future." SNAP PRICE TARGET CUT AT GOLDMAN SACHS: Goldman Sachs analyst Heath Terry lowered his price target for Snap (SNAP) to $11 from $17, while reiterating a Buy rating on the shares. With Snap shares down 50% since the company reported Q2 results, beyond the broader weakness in social media, the analyst believes investors are clearly focused on the impact competition is having on the company's user growth, ability to monetize, and capital needs. Terry continues to believe that a Twitter-like (TWTR) turnaround is possible, particularly as the new Android app comes out of Alpha later this quarter. However, it is unlikely that Q3 results will show any signs of that as reported DAUs decline and engagement is negatively impacted by the redesign/competition, he said.
10/11/18
GSCO
10/11/18
NO CHANGE
Target $11
GSCO
Buy
Snap price target lowered to $11 from $17 at Goldman Sachs
Goldman Sachs analyst Heath Terry lowered his price target for Snap (SNAP) to $11 from $17, while reiterating a Buy rating on the shares. With Snap shares down 50% since the company reported Q2 results, beyond the broader weakness in social media, the analyst believes investors are clearly focused on the impact competition is having on the company's user growth, ability to monetize, and capital needs. Terry continues to believe that a Twitter-like (TWTR) turnaround is possible, particularly as the new Android app comes out of Alpha later this quarter. However, it is unlikely that Q3 results will show any signs of that as reported DAUs decline and engagement is negatively impacted by the redesign/competition, he contends.
10/09/18
10/09/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. WALMART UPPED TO BUY AT DEUTSCHE: Deutsche Bank analyst Paul Trussell upgraded Walmart (WMT) to Buy from Hold and raised his price target for the shares to $113 from $89. The retailer is reaping returns on the many years of investment in e-commerce and customer service, Trussell said. The analyst believes Walmart is now in position to accelerate market share gains in grocery while also growing EBIT dollars and expanding return on investment. He believes Walmart's portfolio of assets is differentiated in the "rapidly changing" retail landscape. In late morning trading, Walmart is up just over 2%. KROGER CUT TO SELL AT DEUTSCHE: Deutsche Bank analyst Paul Trussell downgraded Kroger (KR) to Sell from Hold and lowered his price target for the shares to $24 from $30. Kroger's strategy to aggressively expand e-commerce capabilities, optimize space within current footprint, and compete on price "will likely be significantly more costly than the company and consensus are currently forecasting," Trussell said. The analyst, while believing Kroger may be one of the winners in food retail over the long term, thinks the "period of rapid change" in the grocery sector will likely make it challenging for the company to grow profits "while playing from a position of weakness." JEFFERIES UPGRADES BAKER HUGHES TO BUY: Jefferies analyst Brad Handler upgraded Baker Hughes (BHGE) to Buy from Hold and raised his price target for the shares to $38 from $34. Earnings power of $4 per share next decade "seems tangible," as is free cash flow conversion of greater than 90% of estimated earnings, Handler said. Further, he thinks General Electric (GE) "fire-sale" risk is small. MACQUARIE STARTS TESLA WITH AN OUTPERFORM: Macquarie analyst Maynard Um initiated Tesla (TSLA) with an Outperform rating and $430 price target, stating that he sees the company having unique potential among carmakers to be a leader in in-vehicle ecosystem platforms. In the near-term, Um also thinks Tesla has enough levers to get over its "debt maturity hump," including cash flow from ZEV credits and Model 3 sales, access to $1.2B unused debt commitment, and the potential for credit amendments. MOFFETTNATHANSON SAYS SNAP WILL NEED TO RAISE CAPITAL: MoffettNathanson analyst Michael Nathanson said he is skeptical, despite Snap (SNAP) CEO Evan Spiegel's internal memo, that the company can hit his stated 2019 goal of achieving full year positive free cash flow and profitability. Snap "is quickly running out of money," contends Nathanson, who thinks the company will need to raise capital by the middle to end of 2019. The analyst lowered his revenue estimates for 2019 and 2020 as he anticipates slower DAU and ARPU growth ahead and maintained his Neutral rating on Snap shares, though he cut his price target to $6.50 from $8.
10/12/18
PIVT
10/12/18
UPGRADE
Target $8
PIVT
Buy
Snap upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser upgraded Snap to Buy from Hold while lowering his price target for the shares to $8 from $9. The stock closed yesterday up 22c to $6.81. The analyst says that despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." It is not too late for management to find ways to reverse recent usage trends and generally improve monetization regardless of those usage trends, Wieser tells investors in a research note. Further, the analyst believes Snap could become an attractive candidate to go private with the stock's price at current levels. Wieser views Snap's risk/reward as favorable following the recent selloff.
COST Costco
$225.01

3.15 (1.42%)

10/12/18
NRCS
10/12/18
UPGRADE
NRCS
Buy
Costco upgraded to Buy from Neutral at Northcoast
10/10/18
LOOP
10/10/18
NO CHANGE
Target $265
LOOP
Buy
Costco maintains mid-single-digit growth in all segments, says Loop Capital
Loop Capital analyst Laura Champine kept her Buy rating and $265 price target on Costco after its September SSS increase of 7.3% exceeded consensus expectations of a 6% growth as traffic grew 4.6% and average ticket value grew 3.6% excluding gasoline inflation. The analyst notes that the company continues to absorb inflation in order to maximize its top-line growth, maintaining her FY19 revenue growth outlook of 9% and EPS view of $7.95 - above $7.70 consensus. Champine further cites Costco's mid-single digit or better growth being achieved across its major merchandise categories.
10/05/18
STFL
10/05/18
NO CHANGE
Target $245
STFL
Buy
Costco 'sacrificing margin' to maintain price leadership, says Stifel
Stifel analyst Mark Astrachan noted that Costco's core merchandise gross margin declined 2 basis points in Q4 after a 4 bps decline in the prior quarter, which he believe largely reflects Costco's continued investments in price. On the positive side, membership renewal rates, members per club and sales per member all increased sequentially, noted Astrachan. He believes continued reinvestment is appropriate to sustain outperformance and keeps a Buy rating and $245 price target on Costco shares, which are down 3.5% to $223.52 in pre-market trading.
10/05/18
RBCM
10/05/18
NO CHANGE
Target $253
RBCM
Outperform
Costco price target lowered to $253 at RBC Capital
RBC Capital analyst Scot Ciccarelli lowered his price target on Costco to $253 from $255 after its Q4 results, noting that its gross margins were pressured in the quarter by gasoline inflation and expects those headwinds to persist. The analyst also keeps his Outperform rating, stating that the company's business model remained robust with "some of the best traffic growth in retail". Ciccarelli expects Costco to continue to widen its competitive moat, adding that he would be an "aggressive" buyer on any pullback.

TODAY'S FREE FLY STORIES

VAR

Varian Medical

$104.25

-1.575 (-1.49%)

16:31
10/21/18
10/21
16:31
10/21/18
16:31
Hot Stocks
Varian unveils new Bravos afterloader system for brachytherapy treatments »

Varian announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27
Hot Stocks
BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study »

BioLineRx (BLRX)…

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

ADAP

Adaptimmune

$10.79

-0.09 (-0.83%)

13:22
10/21/18
10/21
13:22
10/21/18
13:22
Hot Stocks
Adaptimmune presents updated data from ongoing MAGE-A10, MAGE-A4 studies »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26
Hot Stocks
Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

12:18
10/21/18
10/21
12:18
10/21/18
12:18
Hot Stocks
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer »

Tesaro summarized updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.